As the number and variety of organisms modeling human neuropathology increase, the number and variety of techniques used to validate these models also continues to expand. Antti Nurmi of Charles River discusses in Drug Discovery News.
Immunogenic assays are a necessity in the development of biotherapeutics. However, they pose daunting developmental challenges. Sebastien Boridy, PhD, Research Scientist of Immunogenicity at Charles River discusses in GEN.
Are you sure your lab is clean? Joan O’Malley, Manager of the Microbiology Department at Charles River, provides tips for making sure your lab disinfectants are working, from selecting the right media to not cross-fertilizing.
Despite limitations, mass spectrometry is having an impact on biologic drug development and manufacturing. Mario DiPaola, Scientific Director at Charles River, discusses the importance of mass spectrometry in BioPharm International.
Dr. Anne-Marie Zuurmond, Associate Director of Genome Engineering at Charles River, spoke with Xtalks about how the CRISPR/Cas9 genome editing tool works and how it could streamline drug discovery.
To develop a disease-relevant phenotypic assay, Charles River developed primary cell-based assays of fibroblasts from skin biopsies of patients. Jeroen DeGroot, PhD, Senior Director of Biology, discusses the use of phenotype screens in scleroderma research in GEN.
Recently, there have been important advances in the application of touch-sensitive screens for testing cognitive behavior in several animal species. Maksym Kopanitsa, PhD, Head of Translational Biology at Charles River, discusses in Drug, Discovery and Development.
Recent news has highlighted the potential risks of CAR T-cell therapies, but there is reason to be optimistic. David Harris, Research Director for Charles River, discusses in The Scientist.
Microsampling is now part of many companies’ workflows within the research and laboratory space and is becoming part of our day-to-day language in bioanalysis and clinical development. Tim Sangster, Head of Bioanalysis and Immunology at Charles River, provides an update on the current state of microsampling.
In the fight against cancer, immunotherapies represent the next frontier. However, they have only been effective in 20–30% of patients. Enter: a better mouse model that makes immunotherapies more translational. Read more from Aidan Synnott of Charles River in STAT.